Literature DB >> 2704584

Acute effects of oxygen, nifedipine, and diltiazem in patients with cystic fibrosis and mild pulmonary hypertension.

A Davidson1, A Bossuyt, I Dab.   

Abstract

The acute effects of oxygen, nifedipine, and diltiazem were studied in eight patients with cystic fibrosis and mild pulmonary hypertension, to assess the possibility of relieving the latter before the occurrence of irreversible vascular changes. Oxygen decreased pulmonary pressure (-23%) and resistance (-21%), while increasing systemic resistance (+23%). Nifedipine increased cardiac index (+30%), at the expense of augmented right ventricular work (+42%), resulting in a decreased calculated pulmonary resistance (-23%); pulmonary artery pressure remained unchanged, however. Nifedipine decreased arterial Po2 (-10%), suggesting ventilation-perfusion mismatch. Four of the eight patients responded to diltiazem. Their pulmonary pressure (-35%) and resistance (-43%) decreased, while systemic vascular tone remained unchanged. Oxygen in three patients, and diltiazem in two, returned pulmonary pressures and resistances to normal values. Early reversal of pulmonary hypertension is possible, and intervention is desirable before the establishment of chronic hypoxia, cor pulmonale, or right ventricular failure. Our data does not support the use of nifedipine in pulmonary hypertension, but shows that oxygen, and in some cases diltiazem, act as effective and selective pulmonary vasodilators.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2704584     DOI: 10.1002/ppul.1950060113

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

Review 1.  The heart in cystic fibrosis.

Authors:  Rowland J Bright-Thomas; A Kevin Webb
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  Severe paediatric pulmonary hypertension: new management strategies.

Authors:  A Rashid; D Ivy
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

Review 3.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  Enhanced store-operated Ca²+ entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats.

Authors:  Xiao-Ru Liu; Ming-Fang Zhang; Na Yang; Qing Liu; Rui-Xing Wang; Yuan-Ning Cao; Xiao-Ru Yang; James S K Sham; Mo-Jun Lin
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-21       Impact factor: 4.249

Review 5.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

6.  Nocturnal oxygen desaturation and spirometric parameters in adults with cystic fibrosis.

Authors:  M N Pond; S P Conway
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

7.  Chronic hypoxia selectively enhances L- and T-type voltage-dependent Ca2+ channel activity in pulmonary artery by upregulating Cav1.2 and Cav3.2.

Authors:  Jun Wan; Aya Yamamura; Adriana M Zimnicka; Guillaume Voiriot; Kimberly A Smith; Haiyang Tang; Ramon J Ayon; Moumita S R Choudhury; Eun A Ko; Jun Wang; Chen Wang; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-05-17       Impact factor: 5.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.